Geoff Farrell
Overview
Explore the profile of Geoff Farrell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
670
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clark P, Valery P, Ward J, Strasser S, Weltman M, Thompson A, et al.
BMC Gastroenterol
. 2022 Jul;
22(1):339.
PMID: 35820850
Background: First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of direct-acting antiviral (DAA) therapy among First Nations...
2.
Clark P, Valery P, Strasser S, Weltman M, Thompson A, Levy M, et al.
Dig Dis Sci
. 2022 May;
68(1):291-303.
PMID: 35552941
Background And Aims: In 2016, direct-acting antiviral (DAA) treatment for hepatitis C (HCV) became available through Australia's universal health care system, with the aim of HCV elimination. We report real-world...
3.
4.
Nguyen T, Wardell R, Chitturi S, Teoh N, Farrell G
J Gastroenterol Hepatol
. 2019 Dec;
35(6):953-959.
PMID: 31867782
Liver stiffness measurement (LSM) by FibroScan-determined transient elastography is a noninvasive approach to estimate liver fibrosis severity. In non-alcoholic fatty liver disease (NAFLD), advanced liver fibrosis is excluded by normal...
5.
6.
Farrell G, Schattenberg J, Leclercq I, Yeh M, Goldin R, Teoh N, et al.
Hepatology
. 2018 Oct;
69(5):2241-2257.
PMID: 30372785
Nonalcoholic steatohepatitis (NASH) arises from a variable interplay between environmental factors and genetic determinants that cannot be completely replicated in animals. Notwithstanding, preclinical models are needed to understand NASH pathophysiology...
7.
Chitturi S, Wong V, Chan W, Wong G, Wong S, Sollano J, et al.
J Gastroenterol Hepatol
. 2017 Jul;
33(1):86-98.
PMID: 28692197
No abstract available.
8.
Wong V, Chan W, Chitturi S, Chawla Y, Dan Y, Duseja A, et al.
J Gastroenterol Hepatol
. 2017 Jul;
33(1):70-85.
PMID: 28670712
No abstract available.
9.
Wu J, Shadbolt B, Teoh N, Blunn A, To C, Rodriguez-Morales I, et al.
J Gastroenterol Hepatol
. 2014 Jun;
29(6):1258-64.
PMID: 24955454
Background And Aim: Pegylated-interferon-α/ribavirin (PEG-IFN/RBV) treatment can cure hepatitis C virus (HCV) infection but has frequent neuropsychiatric side-effects. Patients with pre-existing psychiatric illness may not be offered therapy. We established...
10.
Chitturi S, Wong V, Farrell G
J Gastroenterol Hepatol
. 2011 Jan;
26 Suppl 1:163-72.
PMID: 21199528
Nonalcoholic fatty liver disease (NAFLD) is becoming an important chronic liver disorder in Asia. Prevalence figures show regional variations but at least 10% of the general population in Asia have...